An investigational CBD and THC oral solution for dogs with bone cancer pain is now eligible to pursue an FDA route that could bring it to market before full approval.
An investigational cannabidiol (CBD) and tetrahydrocannabinol (THC) oral solution being developed to control bone cancer pain in dogs is now eligible to pursue conditional approval from the FDA.
The FDA Center for Veterinary Medicine determined that the proposed use of the product, CannEpil, qualifies as a “minor use” under the agency’s Minor Use and Minor Species (MUMS) program, according to an October 5, 2026 announcement from developer Endovia Health Sciences and its development partner, Lupvindol BioSciences.1 The agency also determined that the product will retain its minor-use status through approval of its New Animal Drug Application.1
CannEpil remains an investigational new animal drug and has yet to be approved or conditionally approved by the FDA.1
The MUMS program was created to encourage development of animal drugs for uncommon conditions that affect relatively small populations. Conditional approval is intended to help eligible therapies become available sooner.1
To earn conditional approval, a drug must meet FDA requirements for safety and manufacturing and demonstrate a reasonable expectation of effectiveness, rather than the substantial-evidence standard required for full approval. The sponsor may then legally market the drug while it collects the additional effectiveness data required for full approval. Conditional approval is valid for 1 year and can be renewed annually for up to 4 additional years while the sponsor gathers the necessary data.2
The companies are scheduled to meet with the FDA on November 19, 2026, for a presubmission conference to align on the studies, manufacturing requirements, and regulatory submissions needed to pursue conditional approval.1
Alongside the regulatory work, the companies said they are sourcing and finalizing US-based manufacturing capabilities for the product. That supply chain is intended to support the clinical and regulatory program and, if the necessary approvals come through, a potential veterinary launch in 2027.1 The release noted that this timeline depends on FDA review, completion of regulatory requirements, and manufacturing readiness.
“This determination represents an important regulatory milestone for CannEpil and provides greater clarity around the pathway we are pursuing with the FDA,” Brady Cobb, interim chief executive officer of Endovia Health Sciences, said in the announcement.1 “Importantly, we are not waiting to begin preparing for commercialization.”
Cobb framed the veterinary program as a chance to address what he described as an unmet clinical need.1 “Our veterinary program gives us an opportunity to address a serious unmet need for dogs suffering from cancer-related pain while building the regulatory, manufacturing, and scientific infrastructure that we believe can support the broader development of CannEpil,” he said.
According to the companies, the veterinary program is part of a broader effort to develop cannabinoid-based therapeutics through federal regulatory pathways, with possible future veterinary and human applications.1
References
